ClinicalTrials.gg
TerminatedNCT05427045Updated Nov 7, 2024Results posted

A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis

An interventional study of home - exercise program in Multiple Sclerosis and Back Pain, sponsored by University of Arkansas. Terminated at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by University of Arkansas · Not applicable, Interventional, and Treatment

Why this study was terminated
Incomplete follow up, low enrollment
Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This research study plans to evaluate if multifidus muscle dysfunction is associated with back pain in patients with Multiple Sclerosis (MS).

Read the detailed description

Since the multifidus muscle helps to stabilize the lumbar spine, the investigators hope to learn if there is dysfunction and/or atrophy of this muscle in MS patients who also have back pain. The main objective is to study if it is possible to do a home-exercise program in patients with MS younger then 50 years old and who do not need any assistance to walk. Another objective is to further characterize the multifidus function in those patients. This will be by by measuring the size of muscle at the beginning and end of the study, and also by physical exam. As an exploratory aim, the investigators would like to evaluate the relation between compliance with the home-exercise program and the change in the size of the multifidus muscle and the change in pain.

02

Conditions studied

  • Multiple Sclerosis
  • Back Pain
03

In context

Multiple Sclerosis

3,524 studies on the registry are indexed under Multiple Sclerosis; 668 are open to participants now.

This study's enrollment of 7 is below the median of 50 across 2,386 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

University of Arkansas is the lead sponsor of 398 studies on the registry; 37 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis by an UAMS neuro-immunologist of relapsing-remitting MS or primary progressive MS or secondary progressive MS
  • Age between 18 years old and 50 years old on consent
  • Complain of low back pain or severe axial back pain
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Patients that also have the diagnosis of thoracic or lumbar radiculopathy or history of prior thoracic or lumbar spinal surgery.

Patients that are currently pregnant EDSS over 5.5 or less than 1.0 Patient younger than 18 years old or older than 50 years old Knee total extension of less than 100 degrees

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Intervention group

    Adult patients \< 50 years old who have multiple sclerosis and back pain who are undergoing home exercise

    Other: home - exercise program

Interventions

  • Otherhome - exercise program

    Home exercise program

06

What researchers measure

Primary outcomes

  1. Study the Compliance of a Home-exercise Program in Patients With MS

    we will evaluate how many exercise sessions patients do at home versus what was purposed to the patient.

    Time frame: 6 months

Secondary outcomes

  1. Qualify the Multifidus Dysfunction in Patients With MS - Ultrasound

    evaluation of the change from baseline of a cross-section area of the multifidus muscle measured by ultrasound

    Time frame: 6 months

  2. Qualify the Multifidus Dysfunction in Patients With MS - Physical Exam

    evaluation of the change from baseline of a cross-section area of the multifidus muscle measured by physical exam maneuvers

    Time frame: 6 months

  3. Correlation Between Compliance and Plain and Size of Muscle

    statistical analysis will be done to verify the relation between compliance with the home-exercise program and the change in the cross-section area of the multifidus muscle and the change in pain score using PROMIS scale

    Time frame: 6 months

07

Results

Posted Nov 7, 2024

Participant flow

Participant flow — Overall Study
MilestoneIntervention Group
Started7
Completed1
Not completed6

Outcome measures

PrimaryStudy the Compliance of a Home-exercise Program in Patients With MS

we will evaluate how many exercise sessions patients do at home versus what was purposed to the patient.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryQualify the Multifidus Dysfunction in Patients With MS - Ultrasound

evaluation of the change from baseline of a cross-section area of the multifidus muscle measured by ultrasound

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryQualify the Multifidus Dysfunction in Patients With MS - Physical Exam

evaluation of the change from baseline of a cross-section area of the multifidus muscle measured by physical exam maneuvers

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryCorrelation Between Compliance and Plain and Size of Muscle

statistical analysis will be done to verify the relation between compliance with the home-exercise program and the change in the cross-section area of the multifidus muscle and the change in pain score using PROMIS scale

Time frame:
6 months

No measurements were reported for this outcome.

Adverse events

Collected over 1 year from the time a subject was enrolled. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention Group0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Intervention Group
<=18 years0
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Intervention Group
Female0
Male1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intervention Group
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White0
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 27, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05427045
Responsible party
Sponsor
First posted
Jun 22, 2022
Start date
May 1, 2022
Primary completion
May 5, 2023
Completion
May 5, 2023
Results posted
Nov 7, 2024
Last update
Nov 7, 2024

Study contacts

Erika Santos Horta, MD
principal investigator · University of Arkansas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion